59 related articles for article (PubMed ID: 31043309)
1. Performance of Roche cobas high-risk human papillomavirus (hrHPV) testing in the two most common liquid-based Papanicolaou test platforms.
Fuller MY; Mody RR; Luna E; Armylagos D; Schwartz MR; Mody DR; Ge Y
J Am Soc Cytopathol; 2018; 7(3):142-148. PubMed ID: 31043309
[TBL] [Abstract][Full Text] [Related]
2. Cervical biopsy rates before and after the introduction of human papillomavirus type reporting in co-tests with negative cytology.
Ruff H; Mody D; Luna E; Armylagos D; Thrall MJ
J Am Soc Cytopathol; 2017; 6(5):180-184. PubMed ID: 31043240
[TBL] [Abstract][Full Text] [Related]
3. The reporting rates of atypical glandular cells and their HPV testing and histologic follow-up results: a comparison between ThinPrep and SurePath preparations from a single academic institution.
Liu S; Gibbons-Fideler IS; Tonkovich D; Shen R; Li Z
J Am Soc Cytopathol; 2019; 8(3):128-132. PubMed ID: 31097288
[TBL] [Abstract][Full Text] [Related]
4. A Comparison of the Roche Cobas HPV Test With the Hybrid Capture 2 Test for the Detection of High-Risk Human Papillomavirus Genotypes.
Levi AW; Bernstein JI; Hui P; Duch K; Schofield K; Chhieng DC
Arch Pathol Lab Med; 2016 Feb; 140(2):153-7. PubMed ID: 26910220
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus detection with genotyping by the cobas and Aptima assays: Significant differences in HPV 16 detection?
Chorny JA; Frye TC; Fisher BL; Remmers CL
Diagn Cytopathol; 2018 Jul; 46(7):568-571. PubMed ID: 29573226
[TBL] [Abstract][Full Text] [Related]
6. Comparison of human papillomavirus detection by Aptima HPV and cobas HPV tests in a population of women referred for colposcopy following detection of atypical squamous cells of undetermined significance by Pap cytology.
Castle PE; Eaton B; Reid J; Getman D; Dockter J
J Clin Microbiol; 2015 Apr; 53(4):1277-81. PubMed ID: 25653409
[TBL] [Abstract][Full Text] [Related]
7. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
8. hrHPV positivity in ASC-US Papanicolaou tests from women with treated HPV- and non-HPV-related gynecologic malignancies.
Paintal A; Heagley D
J Am Soc Cytopathol; 2016; 5(4):216-220. PubMed ID: 31042511
[TBL] [Abstract][Full Text] [Related]
9. Resolution of equivocal results with the Hybrid Capture II high-risk HPV DNA test: a cytologic/histologic review of 191 cases.
Knoepp SM; Kuebler DL; Wilbur DC
Diagn Mol Pathol; 2007 Sep; 16(3):125-9. PubMed ID: 17721319
[TBL] [Abstract][Full Text] [Related]
10. Very low human Papillomavirus DNA prevalence in mature women with negative computer-imaged liquid-based Pap tests.
Zhao C; Elishaev E; Yuan KH; Yu J; Austin RM
Cancer; 2007 Oct; 111(5):292-7. PubMed ID: 17879368
[TBL] [Abstract][Full Text] [Related]
11. History of high-risk HPV and Pap test results in a large cohort of patients with invasive cervical carcinoma: experience from the largest women's hospital in China.
Tao X; Griffith CC; Zhou X; Wang Z; Yan Y; Li Z; Zhao C
Cancer Cytopathol; 2015 Jul; 123(7):421-7. PubMed ID: 25955972
[TBL] [Abstract][Full Text] [Related]
12. The clinical performance of computer-assisted liquid-based cytology, primary hrHPV screening, and cotesting at a Turkish Tertiary Care Hospital.
Kir G; Seneldir H; Cosan Sarbay B
Diagn Cytopathol; 2018 Jan; 46(1):3-8. PubMed ID: 29024512
[TBL] [Abstract][Full Text] [Related]
13. The ideal strategy for cervical cancer screening in Japan: Result from the Fukui Cervical Cancer Screening Study.
Kurokawa T; Onuma T; Shinagawa A; Chino Y; Kobayashi M; Yoshida Y
Cytopathology; 2018 Aug; 29(4):361-367. PubMed ID: 29768678
[TBL] [Abstract][Full Text] [Related]
14. Prior high-risk human papillomavirus testing and Papanicolaou test results of 70 invasive cervical carcinomas diagnosed in 2012: results of a retrospective multicenter study.
Zhao C; Li Z; Nayar R; Levi AW; Winkler BA; Moriarty AT; Barkan GA; Rao J; Miller F; Fan F; Zhou Z; Si Q; Fischer AH; Sturgis CD; Jing X; Marshall CB; Witt BL; Birdsong GG; Crothers BA
Arch Pathol Lab Med; 2015 Feb; 139(2):184-8. PubMed ID: 24694342
[TBL] [Abstract][Full Text] [Related]
15. High grade squamous intraepithelial lesion on high-risk HPV negative patients: Why we still need the Pap test.
Sun H; Masand RP; Patel SJ; Padmanabhan V
Diagn Cytopathol; 2018 Nov; 46(11):908-913. PubMed ID: 30488672
[TBL] [Abstract][Full Text] [Related]
16. Genotyping for Human Papillomavirus (HPV) 16/18/52/58 Has a Higher Performance than HPV16/18 Genotyping in Triaging Women with Positive High-risk HPV Test in Northern Thailand.
Khunamornpong S; Settakorn J; Sukpan K; Suprasert P; Srisomboon J; Intaraphet S; Siriaunkgul S
PLoS One; 2016; 11(6):e0158184. PubMed ID: 27336913
[TBL] [Abstract][Full Text] [Related]
17. Managing atypical squamous cells of undetermined significance (ASCUS): human papillomavirus testing, ASCUS subtyping,or follow-up cytology?
Hughes SA; Sun D; Gibson C; Bellerose B; Rushing L; Chen H; Harlow BL; Genest DR; Sheets EE; Crum CP
Am J Obstet Gynecol; 2002 Mar; 186(3):396-403. PubMed ID: 11904597
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework.
Xu L; Oštrbenk A; Poljak M; Arbyn M
J Clin Virol; 2018 Jan; 98():37-42. PubMed ID: 29241150
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus viral load as a useful triage tool for non-16/18 high-risk human papillomavirus positive women: A prospective screening cohort study.
Dong L; Wang MZ; Zhao XL; Feng RM; Hu SY; Zhang Q; Smith JS; Qiao YL; Zhao FH
Gynecol Oncol; 2018 Jan; 148(1):103-110. PubMed ID: 29169614
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
